Trial · NCT07884071
AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy
NCT07884071, Not applicable, Not yet recruiting, European Institute of Oncology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy. Trials, record NCT07884071. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884071
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy
- NCT number
- NCT07884071
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- European Institute of Oncology
- Conditions
- Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Interventions
- Manual manipulation of the feet.
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients that completed the treatment | From enrollment to the follow-up contact at 10 weeks | Adherence to treatment will be measured as the number of subjects that completed all study treatment sessions on the total number of subjects enrolled. |
| Primary | Incidence of local adverse events related to the use of medicated oils during treatement sessions or manual therapy. | From enrollment to the follow-up contact at 10 weeks | Incidence will be calculated as the number of local adverse events related to the use of medicated oils during treatement sessions or manual therapy on the total number of treatment sessions administered. |
| Secondary | Change from baseline in the score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale (QLQ-CIPN20) at 10 weeks. | From enrollment to the follow-up contact at 10 weeks | Impact of treatment on Chemotherapy-induced peripheral neuropathy (CIPN) will be assessed using the QLQ-CIPN20 questionnaire. The QLQ-CIPN20 questionnaire will be administered four times: before the first treatment, at mid-treatment, at the end of treatment, and at follow-up. Higher the resulting score mean higher the CIPN affect the patient. Impact of treatment will be defined by the comparison of initial scoring and post treatment scoring. |
| Secondary | Change from baseline in the score of The McGill Pain Questionnaire (P.R.I.) at 10 weeks. | From enrollment to the follow-up contact at 10 weeks | The McGill Pain Questionnaire (P.R.I.) will be administered before the first treatment, at the end of the treatment, and at follow-up. Higher the resulting score mean higher the paint felt by the patient. Impact of treatment on the reduction of the pain will be defined by the comparison of initial scoring and post treatment scoring. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884071
GET https://conductscience.org/api/trials/v1/NCT07884071/registered